EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April.
Morphosys To Present New Phase 3 MANIFEST-2 Data On Pelabresib In Myelofibrosis In Oral Presentation At 2024 ASCO Annual Meeting menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
24.04.2024 - Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostatPLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety . Seite 1
EQS Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of.